Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Oncology
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Stemline TherapeuticsNY - New York
2 programs1
1
VenetoclaxPhase 21 trial
TagraxofuspPhase 1/21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Stemline TherapeuticsVenetoclax
Stemline TherapeuticsTagraxofusp
Clinical Trials (2)
Total enrollment: 171 patients across 2 trials
Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients
Start: Dec 2025Est. completion: Sep 203133 patients
Phase 2Not Yet Recruiting
Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
Start: Sep 2014Est. completion: Mar 2020138 patients
Phase 1/2Completed
Related Jobs in Oncology
Cell Therapy Account Manager（北陸）
Gilead Sciences
Japan - Tokyo
Just now
Senior Director of Clinical Operations
Arvinas
Remote
1h ago
Specialist, Quality Assurance
Umoja Biopharma
Louisville, Colorado, United States
3h ago
$85K - $105K/yr
Senior Facilities Technician
Umoja Biopharma
Louisville, Colorado, United States
3h ago
Leo Cancer Care: Senior In-House Counsel/General Counsel
Leo Cancer Care
Middleton, Wisconsin
7h ago
Summer Intern - Computational Chemistry & Artificial Intelligence
Arvinas
Remote
9h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space